Cholinesterase inhibitors for the treatment of delirium in non-ICU settings

Keyphrases

• Absence of Evidence 9%
• Acetylcholinesterase Inhibitors (AChEI) 100%
• Adverse Events 18%
• Adverse Outcomes 9%
• Antipsychotics 9%
• Clinical Syndromes 9%
• Cochrane 18%
• Cognitive Impairment 18%
• Cognitive Improvement 9%
• Community Setting 9%
• Comorbid 9%
• Confidence Interval 63%
• Confusion Assessment Method 9%
• Continuous Outcomes 9%
• Delirium 100%
• Delirium Severity 9%
• Dementia 18%
• Dichotomous Outcomes 9%
• Early Risk 9%
• Effective Communication 9%
• Healthcare Environment 9%
• Hospital Costs 9%
• Hospital Setting 9%
• Intervention Costs 18%
• Lack of Data 9%
• Length of Hospital Stay 18%
• Medication Risk 9%
• Methodological Procedures 9%
• Mortality Costs 9%
• Mortality Risk 9%
• Nausea 9%
• Non-intensive Care Unit 100%
• Non-pharmacological Methods 9%
• Placebo 27%
• Quality of Life 9%
• Randomized Controlled Trial 9%
• Reassurance 9%
• Rescue Medication 18%
• Risk of Bias 9%
• Risk Ratio 45%
• Rivastigmine 9%
• Search Methods 9%
• Selection Criteria 9%
• Small Sample Size 9%
• Summary of Findings Table 9%
• Symptom Relief 9%

Medicine and Dentistry

• Acetylcholinesterase Inhibitor 100%
• Adverse Event 16%
• Adverse Outcome 8%
• Clinical Syndrome 8%
• Cognitive Defect 16%
• Delirium 100%
• Drug Therapy 33%
• Emergency Medical Technician 16%
• Health Care Cost 25%
• Intensive Care Unit 100%
• Nausea 8%
• Placebo 25%
• Quality of Life 8%
• Randomized Controlled Trial 8%
• Reassurance 8%
• Rivastigmine 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 16%
• Adverse Outcome 8%
• Antipsychotic 8%
• Cholinesterase Inhibitor 100%
• Cognitive Defect 16%
• Delirium 100%
• Nausea 8%
• Placebo 25%
• Randomized Controlled Trial 8%
• Rivastigmine 8%
• Syndrome 8%